PubMed

Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes.

Hodis HN, Mack WJ, Zheng L, Li Y, Torres M, Sevilla D, Stewart Y, Hollen B, Garcia K, Alaupovic P, Buchanan TA.

Diabetes Care. 2006 Jul;29(7):1545-53.PMID: 16801577 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.

Hedblad B, Zambanini A, Nilsson P, Janzon L, Berglund G.

J Intern Med. 2007 Mar;261(3):293-305.PMID: 17305652 [PubMed - indexed for MEDLINE]Related articles

Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study.

Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA; Troglitazone in Prevention of Diabetes (TRIPOD) study.

Diabetes Care. 2004 Jun;27(6):1365-8.PMID: 15161789 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus.

Sidhu JS, Kaposzta Z, Markus HS, Kaski JC.

Arterioscler Thromb Vasc Biol. 2004 May;24(5):930-4. Epub 2004 Mar 4.PMID: 15001452 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus.

Zheng L, Hodis HN, Buchanan TA, Li Y, Mack WJ.

Am J Cardiol. 2007 Apr 1;99(7):956-60. Epub 2007 Feb 15.PMID: 17398191 [PubMed - indexed for MEDLINE]Related articles

Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes.

Xiang AH, Peters RK, Kjos SL, Ochoa C, Marroquin A, Goico J, Tan S, Wang C, Azen SP, Liu CR, Liu CH, Hodis HN, Buchanan TA.

J Clin Endocrinol Metab. 2005 Apr;90(4):1986-91. Epub 2004 Dec 28.PMID: 15623809 [PubMed - indexed for MEDLINE]Related articlesFree article

Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus.

Ahn CW, Lee HC, Park SW, Song YD, Huh KB, Oh SJ, Kim YS, Choi YK, Kim JM, Lee TH.

Diabetes Res Clin Pract. 2001 Apr;52(1):45-53.PMID: 11182215 [PubMed - indexed for MEDLINE]Related articles

The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial.

Caballero AE, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O'Connor C, Logerfo FW, Horton ES, Veves A.

Metabolism. 2003 Feb;52(2):173-80.PMID: 12601628 [PubMed - indexed for MEDLINE]Related articles

Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.

McMahon GT, Plutzky J, Daher E, Bhattacharyya T, Grunberger G, DiCarli MF.

Diabetes Care. 2005 May;28(5):1145-50.PMID: 15855580 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA.

Diabetologia. 2007 Aug;50(8):1723-31. Epub 2007 May 23.PMID: 17520238 [PubMed - indexed for MEDLINE]Related articles

A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.

Davidson JA, McMorn SO, Waterhouse BR, Cobitz AR.

Clin Ther. 2007 Sep;29(9):1900-14.PMID: 18035190 [PubMed - indexed for MEDLINE]Related articles

Association of C-reactive protein with early-stage carotid atherosclerosis in Japanese patients with early-state type 2 diabetes mellitus.

Mita T, Watada H, Uchino H, Shimizu T, Hirose T, Tanaka Y, Kawamori R.

Endocr J. 2006 Oct;53(5):693-8. Epub 2006 Aug 23.PMID: 16926521 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, Perez A, Provost JC, Haffner SM.

JAMA. 2006 Dec 6;296(21):2572-81. Epub 2006 Nov 13.PMID: 17101640 [PubMed - indexed for MEDLINE]Related articlesFree article

Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

Juurinen L, Kotronen A, Granér M, Yki-Järvinen H.

J Clin Endocrinol Metab. 2008 Jan;93(1):118-24. Epub 2007 Oct 23.PMID: 17956948 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.

Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.

Metabolism. 2007 Oct;56(10):1396-401.PMID: 17884451 [PubMed - indexed for MEDLINE]Related articles

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes.

Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H.

J Clin Endocrinol Metab. 1998 May;83(5):1818-20.PMID: 9589700 [PubMed - indexed for MEDLINE]Related articlesFree article

The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.

Franks PW, Jablonski KA, Delahanty L, Hanson RL, Kahn SE, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group.

Diabetologia. 2007 Dec;50(12):2451-60. Epub 2007 Sep 27.PMID: 17898990 [PubMed - indexed for MEDLINE]Related articlesFree article

Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study.

Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM.

Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):1035-41. Epub 2003 Apr 17.PMID: 12702517 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of troglitazone in young first-degree relatives of patients with type 2 diabetes.

Levin K, Hother-Nielsen O, Henriksen JE, Beck-Nielsen H.

Diabetes Care. 2004 Jan;27(1):148-54.PMID: 14693981 [PubMed - indexed for MEDLINE]Related articlesFree article